Compare SNEX & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNEX | KRYS |
|---|---|---|
| Founded | 1924 | 2015 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.3B |
| IPO Year | 1996 | 2017 |
| Metric | SNEX | KRYS |
|---|---|---|
| Price | $74.48 | $335.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $81.33 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 987.8K | 531.0K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | ★ 3.74 | 1.83 |
| Revenue | ★ $132,378,200,000.00 | $389,130,000.00 |
| Revenue This Year | N/A | $38.74 |
| Revenue Next Year | $4.17 | $32.53 |
| P/E Ratio | ★ $20.02 | $178.69 |
| Revenue Growth | 32.53 | ★ 33.94 |
| 52 Week Low | $68.00 | $130.50 |
| 52 Week High | $141.99 | $382.54 |
| Indicator | SNEX | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 24.57 | 43.97 |
| Support Level | $68.97 | $246.17 |
| Resistance Level | $105.18 | $382.33 |
| Average True Range (ATR) | 4.35 | 17.52 |
| MACD | -5.07 | -5.71 |
| Stochastic Oscillator | 10.57 | 21.50 |
StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.